Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Cited In for PubMed (Select 16230020)

1.

Association of the COQ2 V393A Variant with Parkinson's Disease: A Case-Control Study and Meta-Analysis.

Yang X, Xi J, Zhao Q, Jia H, An R, Liu Z, Xu Y.

PLoS One. 2015 Jun 22;10(6):e0130970. doi: 10.1371/journal.pone.0130970. eCollection 2015.

2.

Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Du X, Pang TY.

Front Psychiatry. 2015 Mar 9;6:32. doi: 10.3389/fpsyt.2015.00032. eCollection 2015. Review.

3.

Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis.

Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, Tan W, Salameh J, McKenna-Yasek DM, Smith T, Peng L, Moore MJ, Brown RH Jr, Cai H, Xu Z.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):E1121-9. doi: 10.1073/pnas.1322641111. Epub 2014 Mar 10.

4.

Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Nuber S, Tadros D, Fields J, Overk CR, Ettle B, Kosberg K, Mante M, Rockenstein E, Trejo M, Masliah E.

Acta Neuropathol. 2014 Apr;127(4):477-94. doi: 10.1007/s00401-014-1255-5. Epub 2014 Feb 8.

5.

Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.

Farrell KF, Krishnamachari S, Villanueva E, Lou H, Alerte TN, Peet E, Drolet RE, Perez RG.

J Neurochem. 2014 Feb;128(4):536-46. doi: 10.1111/jnc.12481. Epub 2013 Nov 20.

6.

Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.

Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Monaghan M, Shen W, Stolyar P, Vasilyev D, Zaleska M, D Hirst W, Dunlop J.

PLoS One. 2013 Aug 1;8(8):e70274. doi: 10.1371/journal.pone.0070274. Print 2013.

7.

Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2.

Diao J, Burré J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Südhof TC, Brunger AT.

Elife. 2013 Apr 30;2:e00592. doi: 10.7554/eLife.00592.

8.

Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.

Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A.

PLoS One. 2013;8(4):e60378. doi: 10.1371/journal.pone.0060378. Epub 2013 Apr 1.

9.

Behavioral abnormalities and Parkinson's-like histological changes resulting from Id2 inactivation in mice.

Havrda MC, Paolella BR, Ward NM, Holroyd KB.

Dis Model Mech. 2013 May;6(3):819-27. doi: 10.1242/dmm.010041. Epub 2012 Dec 20.

10.

New trends in the electrochemical sensing of dopamine.

Jackowska K, Krysinski P.

Anal Bioanal Chem. 2013 Apr;405(11):3753-71. doi: 10.1007/s00216-012-6578-2. Epub 2012 Dec 16. Review.

11.

Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans.

Kuwahara T, Tonegawa R, Ito G, Mitani S, Iwatsubo T.

J Biol Chem. 2012 Mar 2;287(10):7098-109. doi: 10.1074/jbc.M111.237131. Epub 2012 Jan 9.

12.

Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family.

Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL.

J Neurosci. 2011 May 18;31(20):7264-74. doi: 10.1523/JNEUROSCI.6194-10.2011.

13.

Parkinson's disease mouse models in translational research.

Antony PM, Diederich NJ, Balling R.

Mamm Genome. 2011 Aug;22(7-8):401-19. doi: 10.1007/s00335-011-9330-x. Epub 2011 May 11. Review.

14.

Striatal pathology underlies prion infection-mediated hyperactivity in mice.

Gunapala KM, Chang D, Hsu CT, Manaye K, Drenan RM, Switzer RC, Steele AD.

Prion. 2010 Oct-Dec;4(4):302-15. Epub 2010 Oct 22.

15.

Behavioral phenotyping of mouse models of Parkinson's disease.

Taylor TN, Greene JG, Miller GW.

Behav Brain Res. 2010 Jul 29;211(1):1-10. doi: 10.1016/j.bbr.2010.03.004. Epub 2010 Mar 6. Review.

16.

In Vitro Electrochemistry of Biological Systems.

Adams KL, Puchades M, Ewing AG.

Annu Rev Anal Chem (Palo Alto Calif). 2008 Jul 1;1:329.

17.
18.

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Sen S, West AB.

Antioxid Redox Signal. 2009 Sep;11(9):2167-87. doi: 10.1089/ARS.2009.2430.

19.

Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?

Buchman VL, Ninkina N.

Neurotox Res. 2008 Dec;14(4):329-41. doi: 10.1007/BF03033857. Review.

20.

Monitoring rapid chemical communication in the brain.

Robinson DL, Hermans A, Seipel AT, Wightman RM.

Chem Rev. 2008 Jul;108(7):2554-84. doi: 10.1021/cr068081q. Epub 2008 Jun 25. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk